Maravai LifeSciences (NASDAQ:MRVI) Sets New 52-Week High – Here’s Why

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)’s share price reached a new 52-week high on Wednesday . The company traded as high as $7.59 and last traded at $7.4750, with a volume of 2543436 shares. The stock had previously closed at $5.74.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on MRVI. Wells Fargo & Company lifted their price target on Maravai LifeSciences from $5.50 to $6.50 and gave the company an “overweight” rating in a report on Friday, August 7th. Wall Street Zen raised Maravai LifeSciences from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. UBS Group reiterated a “reduce” rating on shares of Maravai LifeSciences in a research note on Wednesday, June 3rd. Weiss Ratings upgraded shares of Maravai LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 29th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $6.00 price target on shares of Maravai LifeSciences in a research report on Friday, May 8th. Two equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $6.25.

Maravai LifeSciences Stock Up 14.8%

The company has a debt-to-equity ratio of 0.49, a current ratio of 4.05 and a quick ratio of 2.98. The business’s fifty day moving average price is $6.21 and its two-hundred day moving average price is $4.55. The stock has a market capitalization of $2.15 billion, a PE ratio of -15.94 and a beta of 0.63.

Maravai LifeSciences (NASDAQ:MRVI) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.02. Maravai LifeSciences had a negative return on equity of 15.70% and a negative net margin of 37.07%.The company had revenue of $51.44 million during the quarter, compared to analysts’ expectations of $48.67 million. On average, equities research analysts forecast that Maravai LifeSciences Holdings, Inc. will post -0.2 EPS for the current fiscal year.

Insider Transactions at Maravai LifeSciences

In other news, General Counsel Kurt Oreshack sold 25,000 shares of the company’s stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of $5.06, for a total value of $126,500.00. Following the sale, the general counsel directly owned 360,767 shares of the company’s stock, valued at $1,825,481.02. This represents a 6.48% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 2.49% of the company’s stock.

Institutional Investors Weigh In On Maravai LifeSciences

Several hedge funds have recently added to or reduced their stakes in MRVI. Royal Bank of Canada raised its stake in shares of Maravai LifeSciences by 49.0% during the 1st quarter. Royal Bank of Canada now owns 9,761 shares of the company’s stock valued at $27,000 after buying an additional 3,209 shares during the last quarter. Quantessence Capital LLC acquired a new position in Maravai LifeSciences in the third quarter valued at approximately $31,000. Abel Hall LLC acquired a new position in Maravai LifeSciences in the third quarter valued at approximately $33,000. CIBC Bancorp USA Inc. purchased a new stake in Maravai LifeSciences in the 3rd quarter worth approximately $33,000. Finally, Virtu Financial LLC acquired a new stake in shares of Maravai LifeSciences during the 4th quarter worth approximately $34,000. 50.25% of the stock is owned by hedge funds and other institutional investors.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.